DK3166628T3 - Terapeutisk anvendelse af knoglemorfogenetiske proteiner - Google Patents

Terapeutisk anvendelse af knoglemorfogenetiske proteiner Download PDF

Info

Publication number
DK3166628T3
DK3166628T3 DK15739658.1T DK15739658T DK3166628T3 DK 3166628 T3 DK3166628 T3 DK 3166628T3 DK 15739658 T DK15739658 T DK 15739658T DK 3166628 T3 DK3166628 T3 DK 3166628T3
Authority
DK
Denmark
Prior art keywords
memorphogenetic
bone
proteins
therapeutical use
therapeutical
Prior art date
Application number
DK15739658.1T
Other languages
English (en)
Inventor
Nicholas W Morrell
Wei Li
Paul D Upton
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51453948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3166628(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Application granted granted Critical
Publication of DK3166628T3 publication Critical patent/DK3166628T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
DK15739658.1T 2014-07-10 2015-07-09 Terapeutisk anvendelse af knoglemorfogenetiske proteiner DK3166628T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1412290.7A GB201412290D0 (en) 2014-07-10 2014-07-10 Novel use
PCT/GB2015/051989 WO2016005756A1 (en) 2014-07-10 2015-07-09 Therapeutic use of bone morphogenetic proteins

Publications (1)

Publication Number Publication Date
DK3166628T3 true DK3166628T3 (da) 2020-03-09

Family

ID=51453948

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15739658.1T DK3166628T3 (da) 2014-07-10 2015-07-09 Terapeutisk anvendelse af knoglemorfogenetiske proteiner
DK19220066.5T DK3669886T3 (da) 2014-07-10 2015-07-09 Knoglemorfogenetiske proteiner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19220066.5T DK3669886T3 (da) 2014-07-10 2015-07-09 Knoglemorfogenetiske proteiner

Country Status (21)

Country Link
US (4) US10336800B2 (da)
EP (3) EP3906936A1 (da)
JP (1) JP6737770B2 (da)
KR (2) KR20230049757A (da)
CN (1) CN106661094B (da)
AU (1) AU2015287397B2 (da)
CA (1) CA2954221C (da)
CY (2) CY1123011T1 (da)
DK (2) DK3166628T3 (da)
ES (2) ES2770073T5 (da)
GB (1) GB201412290D0 (da)
HR (2) HRP20200418T1 (da)
HU (2) HUE054512T2 (da)
LT (2) LT3166628T (da)
MX (2) MX2017000448A (da)
PL (2) PL3669886T3 (da)
PT (2) PT3166628T (da)
RS (2) RS61961B1 (da)
RU (1) RU2733318C2 (da)
SI (2) SI3166628T1 (da)
WO (1) WO2016005756A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
GB201603653D0 (en) * 2016-03-02 2016-04-13 Cambridge Entpr Ltd Combination Therapy
CN110603049A (zh) * 2017-02-06 2019-12-20 阿塞勒隆制药公司 用于治疗心力衰竭的组合物和方法
CA3081152A1 (en) 2017-11-02 2019-05-09 Bayer Aktiengesellschaft Bispecific antibodies binding alk-1 and bmpr-2
CN107760779B (zh) * 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
CN111939245B (zh) * 2019-05-16 2024-03-01 龚笑海 一种心脏治疗和保护的药物组合物
WO2021113544A1 (en) * 2019-12-03 2021-06-10 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
WO2023012318A1 (en) * 2021-08-05 2023-02-09 Actelion Pharmaceuticals Ltd Bmp9 variant polypeptides and uses thereof
CN114317604B (zh) * 2022-03-04 2022-06-17 中国医学科学院阜外医院 一种自发性肺动脉高压模型及构建方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171355A (en) * 1875-12-21 Improvement in driers
EP0592562B1 (en) 1991-06-25 1999-01-07 Genetics Institute, Inc. Bmp-9 compositions
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
AU677849B2 (en) 1993-05-12 1997-05-08 Genetics Institute, Llc BMP-10 compositions
WO1995024474A1 (en) 1994-03-10 1995-09-14 Human Genome Sciences, Inc. Bone morphogenic protein-10
WO1996039431A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Bone morphogenic protein-10
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP1571159A1 (en) † 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
US7741284B2 (en) * 2004-05-12 2010-06-22 Acceleron Pharma Inc. BMP10 propeptides and related methods
WO2006130022A1 (en) 2005-05-30 2006-12-07 Agresearch Limited Modulation of ovulation by agonists and antagonists of bmprii
WO2008014054A2 (en) 2006-07-27 2008-01-31 Centocor, Inc. Bmp-7 variant compositions, methods and uses
CN111518218A (zh) * 2006-11-02 2020-08-11 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
EP2150560A1 (en) * 2007-06-01 2010-02-10 Wyeth Methods and compositions for modulating bmp-10 activity
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
WO2010114833A1 (en) 2009-04-01 2010-10-07 Indiana University Research And Technology Corporation Methods for treating diseases using a bone morphogenetic protein
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
JP6161541B2 (ja) * 2011-02-03 2017-07-12 ゾーマ テクノロジー リミテッド 細菌中の機能的タンパク質発現を向上させるための方法および物質
CN108341863A (zh) 2011-04-20 2018-07-31 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
GB201412290D0 (en) * 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
PT3496739T (pt) * 2016-07-15 2021-06-21 Acceleron Pharma Inc Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar
CN107760779B (zh) 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
PL3166628T3 (pl) 2020-06-15
AU2015287397A1 (en) 2017-02-16
KR20230049757A (ko) 2023-04-13
KR102519869B1 (ko) 2023-04-07
MX2017000448A (es) 2017-08-16
LT3166628T (lt) 2020-04-10
EP3166628A1 (en) 2017-05-17
BR112017000113A2 (pt) 2018-01-02
RU2017102381A (ru) 2018-08-10
SI3669886T1 (sl) 2021-08-31
EP3906936A1 (en) 2021-11-10
RU2733318C2 (ru) 2020-10-01
WO2016005756A1 (en) 2016-01-14
PL3669886T3 (pl) 2021-09-13
DK3669886T3 (da) 2021-05-25
AU2015287397B2 (en) 2020-08-20
JP2017521074A (ja) 2017-08-03
KR20170029576A (ko) 2017-03-15
HUE048924T2 (hu) 2020-09-28
PT3669886T (pt) 2021-05-25
HUE054512T2 (hu) 2021-09-28
SI3166628T1 (sl) 2020-07-31
GB201412290D0 (en) 2014-08-27
MX2020011333A (es) 2020-11-24
US20190359668A1 (en) 2019-11-28
JP6737770B2 (ja) 2020-08-12
US20170209540A1 (en) 2017-07-27
EP3166628B1 (en) 2020-01-01
CN106661094A (zh) 2017-05-10
HRP20210734T1 (hr) 2021-06-11
RS61961B1 (sr) 2021-07-30
US11572396B2 (en) 2023-02-07
CY1124143T1 (el) 2022-05-27
US20170121383A1 (en) 2017-05-04
US10336800B2 (en) 2019-07-02
ES2876124T3 (es) 2021-11-11
EP3166628B2 (en) 2023-07-26
PT3166628T (pt) 2020-04-06
RS60181B1 (sr) 2020-06-30
LT3669886T (lt) 2021-06-10
US20240043485A1 (en) 2024-02-08
ES2770073T5 (es) 2024-03-04
CA2954221A1 (en) 2016-01-14
CA2954221C (en) 2023-02-14
CY1123011T1 (el) 2021-10-29
CN106661094B (zh) 2020-09-08
EP3669886B1 (en) 2021-02-24
RU2017102381A3 (da) 2019-02-28
PL3166628T5 (pl) 2023-11-27
EP3669886A1 (en) 2020-06-24
HRP20200418T1 (hr) 2020-06-26
ES2770073T3 (es) 2020-06-30

Similar Documents

Publication Publication Date Title
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3160470T3 (da) Analoger af pridopidin, fremstilling og anvendelse heraf
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3166628T3 (da) Terapeutisk anvendelse af knoglemorfogenetiske proteiner
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3474802T3 (da) Medicinsk forbinding
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3099800T3 (da) Ekspression og oprensning af crm197 og beslægtede proteiner
DK3139855T3 (da) Scanning af tandløse patienter
DK3129019T3 (da) Medicinsk anvendelse af artemisinin-forbindelser og gephyrin-agonister
DK3307267T3 (da) Behandling af multipel sklerose
DK3199179T3 (da) Formulering af rekombinant fusionsprotein
DK3373874T4 (da) Medicinsk forbinding
DK3237621T3 (da) Varianter af human alpha-galactosidase
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3129001T3 (da) Hsp-fri fremstilling af allergen
DK2897382T3 (da) Forbedring af binaural kilde
DK3151814T3 (da) Behandling af en hudlæsion
DK3374495T3 (da) Forbedrede fremgangsmåder til vævsfremstilling
DK3289875T3 (da) Anvendelse af plantesygdomsbekæmpelsesmidler